{"schema_version":"1.0","type":"article","title":"Big Pharma 集體養馬！血腦屏障為何成了 CNS 新藥必爭入口？","url":"https://drugnews.com.tw/articles/2026-09-08-big-pharma-bbb-delivery.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-08-big-pharma-bbb-delivery.md","lang":"zh-Hant","date":"2026-09-08","publish_at":"2026-09-08T08:00:00+08:00","updated_at":"2026-09-08","category":"商業分析系列","topic":"商業分析系列","tags":["血腦屏障","CNS","藥物遞送","授權交易","阿茲海默症"],"summary":"大藥廠以收購、選擇權及授權布局血腦屏障遞送。本文拆解不同交易買到的權利，區分抗體與AAV路線、遞送和臨床受益，並更新Sanofi停止開發等管線狀態。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"圖1｜含紅血球的血液在上方，藥物經腦微血管內皮向下到腦組織；遞送不等於臨床受益","url":"https://drugnews.com.tw/assets/articles/big-pharma-bbb-delivery/01_bbb_blood_to_brain_bilingual.png"},{"alt":"圖2｜TfR1抗體shuttle在血側結合並內吞，之後分向腦側釋放或滯留分解，ASO與siRNA作用位置另列","url":"https://drugnews.com.tw/assets/articles/big-pharma-bbb-delivery/02_rmt_bilingual_r23.png"},{"alt":"圖3｜Roche的trontinemab抗體shuttle與Genentech授權的STAC-BBB AAV衣殼分列，標明第三期與合作公告時非人靈長類證據","url":"https://drugnews.com.tw/assets/articles/big-pharma-bbb-delivery/03_roche_modalities_bilingual_r24.png"},{"alt":"圖4｜腦部分布、靶點作用與患者臨床受益分成三個證據層，另列安全、貨物可替換性及製造要求","url":"https://drugnews.com.tw/assets/articles/big-pharma-bbb-delivery/04_evidence_bilingual_r1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/big-pharma-bbb-delivery/00_cover_no_text_r2.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-08）。Big Pharma 集體養馬！血腦屏障為何成了 CNS 新藥必爭入口？。https://drugnews.com.tw/articles/2026-09-08-big-pharma-bbb-delivery.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}